3-D mammography detects more invasive cancers and reduces call-back rates

3D mammography detects more invasive cancers and reduces call-back rates
3D mammography detects more invasive cancers and reduces call-back rates, large study published in JAMA finds. Credit: Penn Medicine

Reporting in the June 25 issue of JAMA, researchers from Penn Medicine and other institutions found that 3D mammography—known as digital breast tomosynthesis— found significantly more invasive, or potentially lethal, cancers than a traditional mammogram alone and reduced call-backs for additional imaging. This is the largest study reported to date—with nearly a half a million women—measuring the effectiveness of the technology, and could potentially lead to a change in the standard of care for breast screening.

"It's the most exciting improvement to mammography that I have seen in my career, even more important for than the conversion from film-screen mammography to digital mammography," said senior author Emily F. Conant, MD, chief of Breast Imaging the department of Radiology at the Perelman School of Medicine at the University of Pennsylvania. "3D mammography finds more clinically significant cancers earlier, which is the key so that women have moretreatment options and ultimately better health outcomes."

In the retrospective study, the researchers looked at 281,187 digital mammography examinations and 173,663 examinations with both tomosynthesis and digital mammography between 2010 and 2012. The data set included women from a wide range of screening programs that were both geographically diverse and included both academic and community practices, 13 in total.

Researchers found 41 percent more invasive cancers when women were screened with tomosynthesis plus digital compared to digital mammography alone. The use of tomosynthesis also reduced the number of women called back for unnecessary screenings due to false alarms by 15 percent.

Conventional digital mammography is the most widely-used screening modality for breast cancer, but may yield suspicious findings that turn out not to be cancer, known as false-positives. Such findings are associated with a higher recall rate, or the rate at which women are called back for additional imaging or biopsy that may be deemed unnecessary.

Tomosynthesis, however, allows for 3-D reconstruction of the breast tissue, giving radiologists a clearer view of the overlapping slices of breast tissue. And though a relatively new technology, it has shown promise at reducing recall rates in all groups of patients, including younger women and those with dense , and better detection rates in smaller studies. In 2011, tomosynthesis was approved by the U.S. Food and Drug Administration to be used in combination with standard for .

3D mammography is the only method used for breast cancer imaging that has demonstrated this combined benefit, the authors report. While 3D mammography found more invasive cancers, detection of in situ cancers (non-invasive cancers) was similar to a traditional mammography.

Since October 2011, all screening mammograms at Penn Medicine's Perelman Center for Advanced Center now include tomosynthesis according to Dr. Conant.

"The coming years will be very exciting, as we see further improvements in this innovative technology," said Conant. "This new technology will certainly change the way we screen women."

More information: JAMA, DOI: 10.1001/jama.2014.6095 and DOI: 10.1001/jama.2014.6421

add to favorites email to friend print save as pdf

Related Stories

3-D breast imaging could revolutionize cancer screening

Jun 17, 2014

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive ...

Recommended for you

Vaccines may make war on cancer personal

7 minutes ago

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...

Funding to investigate an alternative to chemotherapy

1 hour ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

Enzyme may be key to cancer progression in many tumors

1 hour ago

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.